The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling
Launched by UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA · Sep 18, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Dep...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy subjects without past or current psychiatric or neurological disorders.
- Exclusion Criteria:
- • History of head injury.
- • Pregnant,menstruating,taking oral contraceptives.
- • Medical or psychiatric illness.
About University Of Electronic Science And Technology Of China
The University of Electronic Science and Technology of China (UESTC) is a leading institution renowned for its research and innovation in electronics and information technology. Established with a commitment to advancing scientific knowledge and fostering technological development, UESTC plays a pivotal role in clinical research, particularly in the integration of electronic technologies with healthcare. The university's robust academic framework, combined with its focus on interdisciplinary collaboration, enables the design and execution of clinical trials that aim to enhance medical practices and improve patient outcomes. Through its dedication to excellence and innovation, UESTC contributes significantly to the advancement of healthcare solutions on both a national and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Trial Officials
Shuxia Yao, Dr
Principal Investigator
University of Electronic Science and Technology of China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported